Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Recent patents reveal novel agents for treating endocrine-related disorders

Aug. 16, 2006

Phase I findings indicate AVR-118 safe in patients with type 2 diabetes

Aug. 16, 2006

New therapeutic agents for metabolic disorders reported in recent patent literature

Aug. 14, 2006

Findings of investigation into patient death in phase II DAC:GRF trial

Aug. 14, 2006

Phase II trial of FM-VP4 on schedule

Aug. 14, 2006

QR-443 prevents cachexia in mice

Aug. 14, 2006

Second analytical method validated for PT-401

Aug. 14, 2006

New insights into HMG-CoA synthase structure reported

Aug. 10, 2006

Taisho and Lilly terminate TS-021 license agreement

Aug. 10, 2006

Mexico first to approve Januvia

Aug. 9, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...